Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for XTLB.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2009. Start Trial.
Date Value
December 31, 2024 5.435M
September 30, 2024 5.717M
June 30, 2024 2.233M
March 31, 2024 2.705M
December 31, 2023 2.22M
September 30, 2023 2.501M
June 30, 2023 2.718M
March 31, 2023 3.081M
December 31, 2022 3.999M
September 30, 2022 4.744M
June 30, 2022 5.563M
March 31, 2022 5.844M
December 31, 2021 5.333M
September 30, 2021 3.079M
June 30, 2021 3.282M
March 31, 2021 4.367M
December 31, 2020 3.612M
September 30, 2020 6.028M
June 30, 2020 6.595M
March 31, 2020 7.025M
December 31, 2019 6.98M
September 30, 2019 8.089M
June 30, 2019 9.345M
March 31, 2019 12.20M
December 31, 2018 8.322M
Date Value
September 30, 2018 7.272M
June 30, 2018 6.238M
March 31, 2018 6.197M
December 31, 2017 3.619M
September 30, 2017 3.62M
June 30, 2017 2.09M
March 31, 2017 3.502M
December 31, 2016 2.687M
September 30, 2016 3.825M
June 30, 2016 4.079M
March 31, 2016 4.386M
December 31, 2015 4.887M
September 30, 2015 7.223M
June 30, 2015 7.63M
March 31, 2015 4.637M
December 31, 2014 4.66M
September 30, 2014 5.393M
June 30, 2014 5.708M
March 31, 2014 6.142M
December 31, 2013 6.265M
September 30, 2013 7.323M
June 30, 2013 6.276M
March 31, 2013 6.826M
December 31, 2012 7.353M
September 30, 2012 7.119M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
BioLineRx Ltd. 16.67M
Kamada Ltd. 269.56M
Can-Fite BioPharma Ltd. --
Galmed Pharmaceuticals Ltd. 13.95M
Revium Recovery, Inc. 18.10M